sábado, 4 de julio de 2015

Terapias de los sentidos: Escuchar Bach


"Cuando oigo alguna de las cantatas de Bach, 
me entran ganas de abrir la ventana 
y gritar que la existencia si merece la pena"



Cuando trabajaba en Lucerna, había una pequeña iglesia cerca del lago en la que el organista tocaba piezas del maestro los domingos por la mañana. Era un momento mágico que jamás olvidaré.
Como tampoco la emoción que sentí al escuchar la sonata número 5 para clave y violín cuando entré por azar una tarde en la iglesi de los jesuitas de la ciudad suiza, en unos momentos de depresión en los que pensaba que nada merecía la pena.

Pedro G. Cuartango / Siempre nos quedará Bach
El Mundo 27.06.2015


viernes, 3 de julio de 2015

Ratón de Biblioteca: Pharmaphobia / Thomas P. Stossel




"Medicine is a business. 
Nevertheless, the conflict-of-interest 
instigators have revived 
those antiquated ideas 
and browbeaten physicians 
and researchers 
who accept industry payments 
as lacking altruism 
and being untrustworthy".
Thomas Stossel


For millennia, human survival depended on our innate abilities to fight pathogens and repair injuries. Only recently has medical science prolonged longevity and improved quality of life. Physicians and academic researchers contribute to such progress, but the principal contributor is private industry that produces the tools – drugs and medical devices – enabling doctors to prevent and cure disease. Heavy regulation and biology’s complexity and unpredictability make medical innovation extremely difficult and expensive. 

Pharmaphobia describes how an ideological crusade, stretching over the last quarter century, has used distortion and flawed logic to make medical innovation even harder in a misguided pursuit of theoretical professional purity. Bureaucrats, reporters, politicians, and predatory lawyers have built careers attacking the medical products industry, belittling its critical contributions to medical innovation and accusing it of non-existent malfeasance: overselling product value, flaunting safety and corrupting physicians and academics who partner with it. The mania has imposed “conflict-of-interest” regulations limiting or banning valuable interactions between industry and physicians and researchers and diverting scarce resources from innovation to compliance. The victims are patients suffering from cancer, dementia, and other serious diseases for which new treatments are delayed, reduced, or eliminated as a result of these pointless regulations. 

With breathtaking detail, Thomas Stossel shows how this attack on doctors who work with industry limits medical innovation and inhibits the process of bringing new products into medical care. (Ver)

miércoles, 1 de julio de 2015

Smart 'S.T.EYE' Será también "wearable*" ...?


Estudiantes ingleses idean un preservativo que cambia de color si contacta con algún patógeno 
ABC / MADRID 24/06/2015 


El preservativo,«ST.EYES», tendría moléculas colocadas en la goma, que atacarían a bacterias y virus de transmisión sexual como el herpes o la sífilis adoptando distintas coloraciones

Los estudiantes de Secundaria del Reino Unido Muaz Nawaz (13 años), Chirag Shah (14 años) y Daanyal ali (14 años), quienes han ganado el Premio TeenThech para la Mejor Idea Innovadora relacionada con el sector de la Salud, han creado un preservativo que cambia de color, cuando contacta con patógenos causantes de enfermedades de transmisión sexual como la chlamydia o el herpes, según informa el portal especializado ScienceAlert.com. 

El preservativo, denominado «ST.EYES», tendría moléculas colocadas en la goma, que atacarían a bacterias y virus específicos. Son precisamente estos componentes los que harían que el preservativo adquiriera diferentes coloraciones, dependiendo de los patógenos presentes. Uno de los chicos que participaron en la creación de «ST.EYE», Daanyaal Ali (14 años), ha señalado que «queríamos hacer algo que hiciera que la detección de enfermedades de transmisión sexual fuera lo más segura posible, para que las personas pueden tomar medidas inmediatas en la intimidad de sus propios hogares sin los procedimientos invasivos de los médicos». 





Será también una "wearable*" a considerar?





Código de colores 

Los creadores han explicado que el «ST.EYE» podría adoptar el verde en el caso de la Chlamydia, el amarillo en el del herpes, el morado para el papiloma humano o el azul por la sífilis. 

Ali ha concluido que «creamos el «ST.EYE» como una nueva forma para la detección de infecciones de transmisión sexualcon el objetivo de ayudar a la próxima generación». Además, ha añadido, que «nos hemos asegurado de que somos capaces de dar seguridad a nuestros usarios y de que puede servir para que las personas sean más responsables». 

 Los jóvenes inventores presentarán su galardonada aportación en el Palacio de Buckingham a finales de año, y también se adjudicarán 1.000 libras (2.000 dólares) por su invención.

(*) wearable: dispositivo que se lleva sobre, debajo o incluido en la ropa y que está siempre encendido, no necesita encenderse y apagarse. Otras de sus características es que permite la multitarea por lo que no requiere dejar de hacer otra cosa para ser usado y puede actuar como extensión del cuerpo o mente del usuario

Ver también:
Meet the new female condom that’s “guaranteed” to give you an orgasm.

martes, 30 de junio de 2015

The High Cost of Care Is Driving Cancer Patients to Bankruptcy NBC



Lauren Baumann is one of the lucky ones. 

Though she has cancer, chronic myeloid leukemia, it is manageable, as long as she takes a daily pill called Gleevec. Gleevec is considered a wonder drug, turning Lauren's leukemia from a death sentence to a disease she and thousands of others can live with. The problem is, even with health insurance and a full-time job, Lauren can't afford the monthly co-pay for Gleevec. It can be as high as $2,000 a month — twice the average mortgage payment in the U.S. 

"I feel like you get punished," says Baumann. "I didn't ask to get cancer; I didn't ask to get sick. I was 26 and I was perfectly healthy."

Now 30, this single mom of 9-year-old Aubrey has scrambled almost every month for the last four years looking for help to pay her medical bills. 

"It's embarrassing. I do have a job; I do make money and I still have to call and beg.

Baumann, who lives in Kentucky, has reached out to churches, charities, and even Gleevec's manufacturer Novartis for assistance, always motivated by her determination to see her daughter grow up. 

 "On days I feel like I can't go on anymore or don't have any fight left in me, all I have to do is look at her and she is my why. She is my reason.

And that is why she is furious at the cost of Gleevec, which she must take for life to manage her chronic form of leukemia. The wholesale price has tripled since it came on the market in 2001, rising from $2,624 a month to $9,210

Gleevec is now a nearly $5 billion-a-year drug for Novartis

Dr. Peter Bach, director of Memorial Sloan Kettering's Center for Health Policy and Outcomes in New York, says Gleevec is one example of a cancer drug market that in his words is "utterly broken." 

 The shortest answer to why cancer drugs are so expensive, said Bach, is "because they can be." (...)

In the last five years, 15 new cancer drugs entered the market with price tags of $10,000 or more. 
Bach says things must change. He wants to tie price to performance

(Más)

 

 Opina PharmaGuy*


  Drug companies should be more pro-active in finding patients like Ms. Baumann who cannot afford their medications and help them BEFORE it becomes big news on national TV. That means not selling the PILL, but a personalized "concierge" service to patients -- especially those who are shelling out high co-pays for their drugs. Like an investment manager who asks about your income and long-term goals before investing your money, pharma needs to pro-actively determine the economic status of patients who take their prescribed medications and automatically enroll qualified patients in their much ballyhooed "patient assistance programs" (PAPs). There should people inside pharma whose job is to do this and to assist people through the process. That's what I call "patient centricity," which is only a buzzword today. 

If Novartis was pro-active and discovered Lauren's problem - and fixed it - before NBC News did, they could have told a much different story about Lauren and Aubrey. How their journey did NOT include selling their house and moving in with elderly grandma. How Lauren and Aubrey survived with dignity and thrived economically thanks to Novartis

Instead, the industry continues to defend high prices using the same old argument - it supports research. Yadda, yadda, yadda. Nobody cares! That's not a human interest story! There's no Aubrey in that story! 

(*) Pharmaguy™ (@pharmaguy) is a "constructive critic" of the pharmaceutical industry. 

Ver también:

Alegaciones de Novartis al defender patente de Gleevec: "sham"...*

UK: El Alcalde (London) Boris Johnson "apuesta" por la I+D Pharma




"London is one of the 
most powerful scientific 
discovery engines in the world,"
Boris Johnson


LONDON (Reuters) -

Banks, investors and big drug companies should consider creating a 10-billion-pound ($15.7 billion) "megafund" to help biotech firms in London and across Britain compete with U.S. rivals, London mayor Boris Johnson said on Thursday. 

 Britain is a leader in academic scientific work and also home to two of the world's top drugmakers - GlaxoSmithKline and AstraZeneca - yet emerging life science companies often find it difficult to secure funding. 

The suggested new pool of debt and equity finance is designed to help plug that gap and is one of a number of ideas being floated at a conference in London bringing together leading figures in industry, finance and research. 

The meeting includes representatives from Eli Lilly, Pfizer, Imperial Innovations, Silicon Valley Bank , the European Investment Bank and JP Morgan. 

 "We hope to harness our role as a global financial center that will bring more life-saving drugs to market and deliver a huge boost to the economy," Johnson said. 

The suggested megafund would be able to invest in multiple drugs at different stages of development, with investors receiving a percentage of the royalties from successful products or licensing revenues that result.

Ver


The proposed creation of the fund follows the launch of MedCity last year to promote life sciences research, development, entrepreneurship and commercialisation in the UK. MedCity executive Eliot Forster suggested that the UK was failing to capitalise on its world-class research base because of a lack of adequate investment in the pharmaceutical and biotech sectors. "If you compare the UK to other leading life sciences hubs, we are extremely competitive – we have huge innovation, creativity and entrepreneurial drive, and we are increasingly agile in translating exciting research into spin-out companies," Forster stated. 
The executive continued "if we want to develop another [GlaxoSmithKline] or AstraZeneca, if we want to get a full return on the investment we put into our research base, and if we want better therapies more quickly, this is an issue we have to address."  

Ver

lunes, 29 de junio de 2015